These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

111 related articles for article (PubMed ID: 4842174)

  • 1. [Chronobiological aspects of experimental leukemia].
    Ratte J; Haus E; Halberg F; Kühl JF; Shiotsuka R; Najarian JS
    Union Med Can; 1974 Jul; 103(7):1201-7. PubMed ID: 4842174
    [No Abstract]   [Full Text] [Related]  

  • 2. Survival and cure of leukemic mice after circadian optimization of treatment with cyclophosphamide and 1-beta-D-arabinofuranosylcytosine.
    Scheving LE; Burns ER; Pauly JE; Halberg F; Haus E
    Cancer Res; 1977 Oct; 37(10):3648-55. PubMed ID: 908013
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Modern aspects of using chronopharmacology in hematology. II. Biorhythms in drug effects].
    Berger J; Mikeska J
    Cas Lek Cesk; 1985 Sep; 124(38-39):1220-2. PubMed ID: 4053157
    [No Abstract]   [Full Text] [Related]  

  • 4. Circadian optimization of the treatment of L1210 leukemia with 1-beta-D-arabinofuranosylcytosine, cyclophosphamide, vincristine and methylprednisolone.
    Burns ER; Scheving LE
    Chronobiologia; 1980; 7(1):41-51. PubMed ID: 7438892
    [No Abstract]   [Full Text] [Related]  

  • 5. Selective chemotherapy for advanced murine L 1210 leukemia by combination of 2' deoxycytidine and lethal doses of cytosine-arabinoside.
    Buchman VM; Svet-Maoldavsky GJ; Lichinitser MR; Mkheidze DM
    Biomedicine; 1977 Jul; 27(5):179-80. PubMed ID: 922116
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Chronochemotherapy of L1210 leukemic mice with cytosine arabinoside or cyclophosphamide.
    Rose WC; Trader MW; Laster WR; Schabel FM
    Cancer Treat Rep; 1978 Sep; 62(9):1337-49. PubMed ID: 688277
    [No Abstract]   [Full Text] [Related]  

  • 7. Combined chronochemotherapy of L1210 leukemic mice using 1-beta-D-arabinofuranosylcytosine, cyclophosphamide, vincristine, methylprednisolone and cis-diamminedichloroplatinum.
    Scheving LE; Burns ER; Halberg F; Pauly JE
    Chronobiologia; 1980; 7(1):33-40. PubMed ID: 7192203
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Chronochemotherapy: L 1210 leukemia and beyond.
    Halberg F; Nelson W; Cornélissen G; Haus E; Scheving LE; Good RA
    Chronobiologia; 1979; 6(3):203-11. PubMed ID: 520097
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Studies of the L1210 antileukemic activity of O-2,2'-cyclocytidine, monoacetate (anhydro-ara-C; NSC-129220)--comparison with cytosine arabinoside (NSC-63878) with respect to treatment schedule dependency.
    Venditti JM; Baratta MC; Greenberg NH; Abbott BJ; Kline I
    Cancer Chemother Rep; 1972 Aug; 56(4):483-92. PubMed ID: 5081591
    [No Abstract]   [Full Text] [Related]  

  • 10. Role of liposome type and route of administration in the antitumor activity of liposome-entrapped 1-beta-D-arabinofuranosylcytosine against mouse L1210 leukemia.
    Rustum YM; Dave C; Mayhew E; Papahadjopoulos D
    Cancer Res; 1979 Apr; 39(4):1390-5. PubMed ID: 421223
    [No Abstract]   [Full Text] [Related]  

  • 11. Schedule-dependent synergism for the combination of 1-beta-D-arabinofuranosylcytosine and daunorubicin.
    Edelstein M; Vietti T; Valeriote F
    Cancer Res; 1974 Feb; 34(2):293-7. PubMed ID: 4810905
    [No Abstract]   [Full Text] [Related]  

  • 12. Increased tolerance of leukemic mice to arabinosyl cytosine with schedule adjusted to circadian system.
    Haus E; Halberg F; Pauly JE; Cardoso S; Kühl JF; Sothern RB; Shiotsuka RN; Hwang DS
    Science; 1972 Jul; 177(4043):80-2. PubMed ID: 5041782
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Enhancement by tetrahydrouridine of 1-beta-D-arabinofuranosylcytosine (cytarabine) oral activity in L1210 leukemic mice.
    Neil GL; Moxley TE; Manak RC
    Cancer Res; 1970 Aug; 30(8):2166-72. PubMed ID: 4990003
    [No Abstract]   [Full Text] [Related]  

  • 14. Dose-related synergism of cytosine arabinoside and methotrexate against murine leukemia L1210.
    Avery TL; Roberts D
    Eur J Cancer (1965); 1974 Jul; 10(7):425-9. PubMed ID: 4457345
    [No Abstract]   [Full Text] [Related]  

  • 15. Antitumor activity of a water-insoluble compound entrapped in liposomes on L1210 leukemia in mice.
    Brassinne C; Atassi G; Frühling J; Penasse W; Coune A; Hildebrand J; Ruysschaert JM; Laduron C
    J Natl Cancer Inst; 1983 Jun; 70(6):1081-6. PubMed ID: 6574278
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antitumor effect of 1-beta-D-arabinofuranosylcytosine 5'-adamantoate (NSC 117614) in L1210 leukemic mice.
    Neil GL; Wiley PF; Manak RC; Moxley TE
    Cancer Res; 1970 Apr; 30(4):1047-54. PubMed ID: 5504347
    [No Abstract]   [Full Text] [Related]  

  • 17. Effects of 4,4'-diacetyl-diphenyl-urea-bis(guanylhydrazone) on leukemia L1210.
    Mihich E; Mulhern AI
    Cancer Res; 1968 Feb; 28(2):354-62. PubMed ID: 5641525
    [No Abstract]   [Full Text] [Related]  

  • 18. Scheduling of arabinosylcytosine and 6-thioguanine therapy.
    LePage GA; White SC
    Cancer Res; 1973 May; 33(5):946-9. PubMed ID: 4703126
    [No Abstract]   [Full Text] [Related]  

  • 19. Chemotherapy of leukemia L1210 in mice with 1-beta-d-arabinofuranosylcytosine hydrochloride. I. Influence of treatment schedules.
    Kline I; Venditti JM; Tyrer DD; Goldin A
    Cancer Res; 1966 May; 26(5):853-9. PubMed ID: 5936445
    [No Abstract]   [Full Text] [Related]  

  • 20. The experimental antitumour properties of three congeners of the acridylmethanesulphonanilide (AMSA) series.
    Cain BF; Atwell GJ
    Eur J Cancer (1965); 1974 Aug; 10(8):539-49. PubMed ID: 4463003
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.